Alexander K. Knuth
#159,867
Most Influential Person Now
Alexander K. Knuth's AcademicInfluence.com Rankings
Alexander K. Knuthbiology Degrees
Biology
#12567
World Rank
#16051
Historical Rank
Immunology
#842
World Rank
#865
Historical Rank
Biochemistry
#2154
World Rank
#2299
Historical Rank
Download Badge
Biology
Alexander K. Knuth's Degrees
- Masters Biochemistry Stanford University
- Bachelors Biology University of California, Berkeley
Similar Degrees You Can Earn
Why Is Alexander K. Knuth Influential?
(Suggest an Edit or Addition)Alexander K. Knuth's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. (1991) (3087)
- Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. (2000) (1970)
- Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes (1998) (759)
- A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens (1998) (745)
- Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. (2008) (670)
- [Systemic therapy for colorectal cancer]. (2005) (507)
- A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. (2007) (491)
- Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. (2000) (455)
- Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3 (1995) (447)
- Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. (2000) (420)
- Classification of current anticancer immunotherapies (2014) (357)
- Selective Survival of Naturally Occurring Human CD4+CD25+Foxp3+ Regulatory T Cells Cultured with Rapamycin1 (2007) (354)
- Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma (1997) (340)
- NY-ESO-1: review of an immunogenic tumor antigen. (2006) (336)
- Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. (1998) (328)
- Granulocyte‐macrophage‐colony‐stimulating factor enhances immune responses to melanoma‐associated peptides in vivo (1996) (325)
- Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic‐T‐cell responses: Evidence for immunoselection of antigen‐loss variants in vivo (1996) (319)
- Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation (2012) (311)
- Expression of MAGE genes in primary and metastatic cutaneous melanoma (1995) (297)
- Generation of cytotoxic T‐cell responses with synthetic melanoma‐associated peptides in vivo: Implications for tumor vaccines with melanoma‐associated antigens (1996) (268)
- SSX: A multigene family with several members transcribed in normal testis and human cancer (1997) (250)
- Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma (2000) (249)
- Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens (1989) (238)
- Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses (2003) (230)
- T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. (1984) (229)
- Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. (1985) (219)
- Aldara activates TLR7-independent immune defence (2013) (219)
- Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients (2006) (218)
- Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. (1989) (217)
- Production of stable cytolytic T‐cell clones directed against autologous human melanoma (1987) (214)
- Antigens recognized by autologous antibody in patients with renal‐cell carcinoma (1999) (194)
- Presence on a human melanoma of multiple antigens recognized by autologous CTL (1989) (194)
- Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial (2007) (189)
- Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. (2004) (188)
- Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. (2002) (185)
- Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. (2001) (182)
- A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients (2004) (173)
- Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. (2008) (173)
- Humoral immune responses of cancer patients against “Cancer‐Testis” antigen NY‐ESO‐1: Correlation with clinical events (1999) (156)
- Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. (2001) (144)
- Identification of cancer/testis genes by database mining and mRNA expression analysis (2002) (142)
- Clinical cancer vaccine trials. (2002) (139)
- Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma (2013) (137)
- Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. (1999) (136)
- Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. (1996) (133)
- Cancer-testis antigens and ING1 tumor suppressor gene product are breast cancer antigens: characterization of tissue-specific ING1 transcripts and a homologue gene. (1999) (131)
- Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody. (1984) (123)
- γ-Radiation Promotes Immunological Recognition of Cancer Cells through Increased Expression of Cancer-Testis Antigens In Vitro and In Vivo (2011) (123)
- Rational development of high-affinity T-cell receptor-like antibodies (2009) (120)
- Memory and Effector CD8 T-cell Responses After Nanoparticle Vaccination of Melanoma Patients (2010) (120)
- Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. (2000) (120)
- Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. (1996) (119)
- Consensus nomenclature for CD8+ T cell phenotypes in cancer (2015) (118)
- Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response. (2015) (117)
- New derivatives of vitamin B12 show preferential targeting of tumors. (2008) (111)
- Analysis of antigens recognized on human melanoma cells by A2‐restricted cytolytic t lymphocytes (CTL) (1993) (106)
- Clonal expansion of melan a‐specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma‐associated peptides (2000) (104)
- Antigen‐specific immunotherapy and cancer vaccines (2003) (104)
- Particle size and activation threshold: a new dimension of danger signaling. (2010) (95)
- Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. (1996) (95)
- Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. (2004) (94)
- Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas (2005) (93)
- Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial (2003) (89)
- CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients (2002) (89)
- Serological cloning of a melanocyte rab guanosine 5'-triphosphate-binding protein and a chromosome condensation protein from a melanoma complementary DNA library. (2000) (86)
- A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer (2019) (85)
- Immunohistochemical localization of ganglioside GD3 in human malignant melanoma, epithelial tumors, and normal tissues. (1985) (83)
- Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. (2003) (80)
- Quantitative Computed Tomography Liver Perfusion Imaging Using Dynamic Spiral Scanning With Variable Pitch: Feasibility and Initial Results in Patients With Cancer Metastases (2010) (79)
- Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors (2014) (78)
- Vaccination for Malignant Melanoma: Recent Developments (2000) (76)
- Gemcitabine depletes regulatory T‐cells in human and mice and enhances triggering of vaccine‐specific cytotoxic T‐cells (2011) (72)
- NY‐ESO‐1 protein expression in primary breast carcinoma and metastases—correlation with CD8+ T‐cell and CD79a+ plasmacytic/B‐cell infiltration (2007) (71)
- Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts. (2010) (69)
- Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naïve Prostate Cancer Patients (2010) (68)
- Treatment of POEMS syndrome with bevacizumab (2007) (66)
- IFN-gamma-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma. (1997) (66)
- Cellular immune response to human renal‐cell carcinomas: Definition of a common antigen recognized by HLA‐A2‐restricted cytotoxic T‐Lymphocyte (CTL) clones (1994) (66)
- Cross-Presentation of HLA Class I Epitopes from Exogenous NY-ESO-1 Polypeptides by Nonprofessional APCs 1 (2003) (65)
- Frequent expression of the novel cancer testis antigen MAGE‐C2/CT‐10 in hepatocellular carcinoma (2009) (65)
- How Useful is PET/CT Imaging in the Management of Post‐Transplant Lymphoproliferative Disease After Liver Transplantation? (2006) (62)
- Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. (2005) (62)
- Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC. (2003) (60)
- Virus‐like particles for vaccination against cancer (2019) (60)
- Identification of tumor-restricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum. (2002) (60)
- Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals (1996) (58)
- Quantitative Perfusion Analysis of Malignant Liver Tumors: Dynamic Computed Tomography and Contrast-Enhanced Ultrasound (2012) (56)
- Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia (2004) (55)
- MAGE-C2/CT10 Protein Expression Is an Independent Predictor of Recurrence in Prostate Cancer (2011) (54)
- LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. (2007) (54)
- Automated tube potential selection for standard chest and abdominal CT in follow-up patients with testicular cancer: comparison with fixed tube potential (2012) (54)
- A pilot study of whole body hyperthermia and carboplatin in platinum-resistant ovarian cancer. (2001) (53)
- Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning (2004) (53)
- T cell responses to human malignant tumours. (1992) (52)
- Cancer-Testis Antigens and Immunosurveillance in Human Cutaneous Squamous Cell and Basal Cell Carcinomas (2010) (51)
- The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial (2006) (51)
- Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen‐A family and NY‐ESO‐1 cancer‐testis antigens represents an independent marker for poor survival in head and neck cancer (2014) (51)
- CTL-defined Cancer Vaccines: Perspectives for Active Immunotherapeutic Interventions in Minimal Residual Disease (2004) (51)
- Radiotherapy of Human Sarcoma Promotes an Intratumoral Immune Effector Signature (2013) (51)
- NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy (2007) (50)
- Recombinant antigen expression on yeast surface (RAYS) for the detection of serological immune responses in cancer patients. (2003) (50)
- Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m2 Every 4 Weeks in Previously Treated Patients with Metastatic Breast Cancer (2006) (48)
- Phase I study of a chloroquine–gemcitabine combination in patients with metastatic or unresectable pancreatic cancer (2017) (47)
- Induction of immunogenicity of a human renal‐cell carcinoma cell line by TAP1‐gene transfer (1999) (47)
- Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes. (2005) (46)
- Molecular analysis of the HLA-A2 antigen loss by melanoma cells SK-MEL-29.1.22 and SK-MEL-29.1.29. (1998) (46)
- Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy. (2010) (45)
- Lysis of human pancreatic adenocarcinoma cells by autologous hla‐class I‐restricted cytolytic T‐lymphocyte (CTL) clones (1993) (45)
- Intracellular tumor-associated antigens represent effective targets for passive immunotherapy. (2012) (45)
- Expression of MAGE-C1/CT7 and MAGE-C2/CT10 Predicts Lymph Node Metastasis in Melanoma Patients (2011) (44)
- Daily Pomegranate Intake Has No Impact on PSA Levels in Patients with Advanced Prostate Cancer - Results of a Phase IIb Randomized Controlled Trial (2013) (43)
- Cytogenetic characterization of three human and three rat medullary thyroid carcinoma cell lines. (1995) (43)
- MAGE‐C1/CT‐7 expression in plasma cell myeloma: Sub‐cellular localization impacts on clinical outcome (2008) (43)
- Preferential Nuclear and Cytoplasmic NY-BR-1 Protein Expression in Primary Breast Cancer and Lymph Node Metastases (2006) (42)
- Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial. (1995) (42)
- Expression and function of the peptide transporters in escape variants of human renal cell carcinomas. (1997) (41)
- Tissue distribution of the T cell activation antigen Ta1. Serological, immunohistochemical and biochemical investigations. (1988) (41)
- Patupilone (Epothilone B) for Recurrent Glioblastoma: Clinical Outcome and Translational Analysis of a Single-Institution Phase I/II Trial (2012) (41)
- Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up? (2010) (41)
- Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51. (2002) (39)
- Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy. (2001) (39)
- Computed Tomographic Perfusion Imaging for the Prediction of Response and Survival to Transarterial Radioembolization of Liver Metastases (2013) (39)
- Long-term survival in a patient with Rosai-Dorfman disease treated with interferon-alpha. (1995) (39)
- An Open-Label, Noncomparative Phase II Trial to Evaluate the Efficacy and Safety of Docetaxel in Combination with Gefitinib in Patients with Hormone-Refractory Metastatic Prostate Cancer (2007) (39)
- A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma (2012) (38)
- Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas. (1996) (37)
- Targeted therapy of renal cell carcinoma: Synergistic activity of cG250‐TNF and IFNg (2009) (37)
- NY-BR-1 is a Differentiation Antigen of the Mammary Gland (2007) (36)
- NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma. (2013) (35)
- Cancer immunotherapy in clinical oncology (2000) (35)
- MAGEC2 is a sensitive and novel marker for seminoma: a tissue microarray analysis of 325 testicular germ cell tumors (2011) (35)
- Strong immunogenic potential of a B7 retroviral expression vector: generation of HLA-B7-restricted CTL response against selectable marker genes. (1998) (33)
- Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. (2017) (32)
- MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma (2008) (31)
- The differentiation antigen NY‐BR‐1 is a potential target for antibody‐based therapies in breast cancer (2007) (30)
- Vaccination with nanoparticles combined with micro-adjuvants protects against cancer (2019) (30)
- Tumor Imaging in Patients with Advanced Tumors Using a New 99mTc-Radiolabeled Vitamin B12 Derivative (2014) (30)
- A Systemic Hyperthermia Oncologic Working Group Trial (2003) (30)
- Spontaneous CD8 T Cell Responses against the Melanocyte Differentiation Antigen RAB38/NY-MEL-1 in Melanoma Patients1 (2006) (30)
- Cytoskeletal heterogeneity of an epithelioid sarcoma with expression of vimentin, cytokeratins, and neurofilaments. (1990) (28)
- Tumor‐reactive CD8+ T‐cell clones in patients after NY‐ESO‐1 peptide vaccination (2007) (28)
- Radiotherapy supports protective tumor-specific immunity (2012) (28)
- Human tankyrases are aberrantly expressed in colon tumors and contain multiple epitopes that induce humoral and cellular immune responses in cancer patients (2008) (27)
- Structure-Activity Profiles of Ab-Derived TNF Fusion Proteins1 (2006) (26)
- Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: First report of FAPME, a phase I clinical trial. (2020) (26)
- Signet ring stomach cancer: morphological characterization and antigenic profile of a newly established cell line (Mz-Sto-1). (1987) (26)
- Efficient Generation of Multipotent Mesenchymal Stem Cells from Umbilical Cord Blood in Stroma-Free Liquid Culture (2010) (26)
- Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients (2006) (25)
- Pillars Article: A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma. Science 1991. 254: 1643–1647. (2007) (25)
- Antibodies and vaccines--hope or illusion? (2005) (25)
- Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine (2019) (25)
- Messenger RNA vaccination in NSCLC: Findings from a phase I/IIa clinical trial. (2011) (25)
- A human renal cancer line as a new antigen source for the detection of antibodies to cytoplasmic and nuclear antigens in sera of patients with Wegener's granulomatosis. (1991) (25)
- Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients (2009) (24)
- Cellular and humoral immune responses against cancer: implications for cancer vaccines. (1991) (24)
- Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - a phase II study. (2009) (24)
- Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP (2010) (23)
- Fine analysis of spontaneous MAGE-C1/CT7–specific immunity in melanoma patients (2010) (23)
- Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells (1994) (22)
- Hepatocellular carcinoma after thorotrast exposure: Establishment of a new cell line (Mz‐Hep‐1) (1985) (22)
- Potential use of humanized antibodies in the treatment of breast cancer (2006) (22)
- Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study (2018) (22)
- Liver perfusion imaging in patients with primary and metastatic liver malignancy: prospective comparison between 99mTc-MAA spect and dynamic CT perfusion. (2012) (21)
- A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy. (2013) (21)
- Cancer testis antigen expression in testicular germ cell tumorigenesis (2014) (21)
- Distinct expression patterns of the immunogenic differentiation antigen NY‐BR‐1 in normal breast, testis and their malignant counterparts (2007) (21)
- Immunosuppression and lung cancer of donor origin after bilateral lung transplantation. (2012) (21)
- Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome. (2008) (21)
- Antibody response to a non‐conserved C‐terminal part of human histone deacetylase 3 in colon cancer patients (2005) (20)
- Strategies for the development of vaccines to treat breast cancer. (1998) (20)
- β6‐integrin serves as a novel serum tumor marker for colorectal carcinoma (2019) (20)
- Imagine a world without cancer (2014) (19)
- Improved detection of melanoma antigen‐specific T cells expressing low or high levels of CD8 by HLA‐A2 tetramers presenting a Melan‐A/Mart‐1 peptide analogue (2002) (19)
- The form of NY-ESO-1 antigen has an impact on the clinical efficacy of anti-tumor vaccination. (2011) (19)
- Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo (2008) (18)
- A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells (2019) (18)
- Secretory epithelial cell marker on gastrointestinal tumors and in human secretions defined by a monoclonal antibody. (1987) (18)
- Innovation can improve and expand aspects of end-of-life care in low- and middle-income countries. (2014) (17)
- Temsirolimus Is Highly Effective as Third-Line Treatment in Chromophobe Renal Cell Cancer (2011) (17)
- High dose 5-fluorouracil (5-FU) and folinic acid in advanced colorectal cancer resistant to standard dose 5-FU treatment: results of a phase II study. (1995) (16)
- Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas (2013) (16)
- Increased bone marrow activity on F-18-FDG PET/CT in granulocyte colony stimulating factor producing anaplastic thyroid carcinoma. (2010) (16)
- Messenger RNA vaccination and B-cell responses in NSCLC patients. (2012) (16)
- Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim (2010) (16)
- Natural antibodies in human sera directed against blood‐group‐related determinants expressed on colon cancer cells (1983) (15)
- Sequential methotrexate and 5-fluorouracil (FU) vs. FU alone in metastatic colorectal cancer. Results of a randomized multicenter trial. The Association of Medical Oncology (AIO) of the German Cancer Society. (1992) (15)
- HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones. (2004) (14)
- Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma‐associated antigen MART‐1/Melan‐A (1999) (14)
- Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers (2015) (14)
- Peptide Vaccination in Clinical Oncology (2000) (14)
- Second-line treatment with high-dose 5-fluorouracil and folinic acid in advanced colorectal cancer refractory to standard-dose 5-fluorouracil treatment. (1995) (13)
- A common epithelial cell surface antigen (EPM-1) on gastrointestinal tumors and in human sera. (1987) (13)
- Frequent expression of the breast differentiation antigen NY‐BR‐1 in mammary and extramammary Paget's disease (2010) (13)
- Functional autoantibodies against serpin E2 in rheumatoid arthritis. (2010) (13)
- Induction of tumor‐cell lysis by bi‐specific antibody recognizing ganglioside GD2 and T‐cell antigen CD3 (1993) (13)
- Monitoring CD 8 T cell responses to NY-ESO-1 : correlation of humoral and cellular immune responses (2017) (13)
- The discovery of cancer/testis antigens by autologous typing with T cell clones and the evolution of cancer vaccines. (2012) (12)
- Selective Intra-arterial Chemotherapy with Floxuridine as Second- or Third-Line Approach in Patients with Unresectable Colorectal Liver Metastases (2011) (12)
- Vaccination Against Amyloidogenic Aggregates in Pancreatic Islets Prevents Development of Type 2 Diabetes Mellitus (2020) (12)
- Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2) (2015) (12)
- A dose-escalating phase I study with valproic acid (VPA) in patients (pts) with advanced cancer. (2004) (12)
- Successful Salvage Chemotherapy with FOLFIRINOX for Recurrent Mixed Acinar Cell Carcinoma and Ductal Adenocarcinoma of the Pancreas in an Adolescent Patient (2013) (12)
- Combination fluorouracil, folinic acid, and interferon alfa-2a: an active regimen in advanced pancreatic carcinoma. (1992) (12)
- Impact of Antigen Presentation on TCR Modulation and Cytokine Release: Implications for Detection and Sorting of Antigen-Specific CD8+ T Cells Using HLA-A2 Wild-Type or HLA-A2 Mutant Tetrameric Complexes1 (2002) (12)
- Identification of new NY‐ESO‐1 epitopes recognized by CD4+ T cells and presented by HLA‐DQ B1 03011 (2006) (12)
- Target level blocking of T-cell cytotoxicity for human malignant melanoma by monoclonal antibodies. (1984) (11)
- Combination of 5-fluorouracil, adriamycin, ifosfamide and cisplatin in metastatic adult soft tissue sarcoma: results of a phase II study. (1996) (11)
- Original article: Sequential methotrexate and 5-fluorouracil (FU) vs. FU alone in metastatic colorectal cancer Results of a randomized multicenter trial (1992) (11)
- [Regional chemotherapy of liver metastases of colorectal carcinoma using implanted gas pressure pumps. Results of a prospective phase II study]. (2008) (11)
- Use of irradiated mouse fibroblasts to improve the cloning and adaptation to culture of human melanoma cells (1985) (10)
- An open invitation to the cancer immunology community. (2012) (10)
- Treatment of refractory colorectal carcinomas with fluorouracil, folinic acid, and interferon alfa-2a. (1992) (10)
- Induction of tumour cell lysis by a bispecific antibody recognising epidermal growth factor receptor (EGFR) and CD3. (1994) (10)
- Cryptic Epitopes Induce High-Titer Humoral Immune Response in Patients with Cancer (2010) (10)
- Urine antibody against human cancer antigen NY-ESO-1. (2002) (10)
- RP1 Is a Phosphorylation Target of CK2 and Is Involved in Cell Adhesion (2013) (10)
- Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. (2011) (10)
- Combination 5-fluorouracil (FU), folinic acid (FA), and alpha-interferon 2B in advanced gastric cancer: results of a phase II trial. (1995) (9)
- Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma--a randomised pilot study. (1995) (9)
- Performance of different data sources in identifying adverse drug events in hospitalized patients (2011) (9)
- Developments in Cancer Immunotherapy (2010) (9)
- Correction to: Vaccination with nanoparticles combined with micro-adjuvants protects against cancer (2019) (9)
- New cell lines of gastric and pancreatic cancer: distinct morphology, growth characteristics, expression of epithelial and immunoregulatory antigens (2004) (8)
- Long-term Complete Remission Following Radiosurgery and Immunotherapy in a Melanoma Patient with Brain Metastasis: Immunologic Correlates (2014) (8)
- Equivalence of Pegfilgrastim and Filgrastim in Lymphoma Patients Treated with BEAM Followed by Autologous Stem Cell Transplantation (2010) (8)
- Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2) (2015) (8)
- Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study (2021) (8)
- Sequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8. (2009) (8)
- Spontaneous Peripheral T-cell Responses toward the Tumor-Associated Antigen Cyclin D1 in Patients with Clear Cell Renal Cell Carcinoma (2013) (7)
- NY‐ESO‐1 protein glycosylated by yeast induces enhanced immune responses (2010) (7)
- Gemcitabin/Cisplatin vs. MVAC (2003) (7)
- Status of hepatocellular carcinoma in Gulf region. (2013) (7)
- Neutrophil expression of ICAM1, CXCR1, and VEGFR1 in patients with breast cancer before and after adjuvant chemotherapy. (2014) (7)
- Yeast-based identification of prostate tumor antigens provides an effective vaccine platform. (2010) (6)
- Vincristine, doxorabicin, cyclophosphamide, prednisone and etoposide (VACPE) in high-grade non-Hodgkin's lymphoma — a multicenter phase II study (1995) (6)
- An in vitro model for the study of human parathyroid gland tissue: Single cell suspensions and monolayer cultures (1982) (6)
- Autologous stem cell transplantation: leukapheresis product has anti-angiogenic effects in vivo correlating with neutrophil-derived VEGFR1. (2011) (5)
- Combination 5-fluorouracil (FU), folinic acid (FA) and alpha-interferon 28 (IFN) in advanced gastric cancer (1993) (5)
- Dose Escalation Study for Defining the Maximum Tolerated Dose of Continuous Oral Trofosfamide in Pretreated Patients with Metastatic Lung Cancer (2004) (5)
- Prognostic factors for survival in lymphoma patients after autologous stem cell transplantation. (2013) (5)
- Uncommon case of brain metastasis in a patient with a history of heavy smoking. (2014) (5)
- Is an aggressive surgical approach worthwhile in biliary cancer? (2007) (5)
- The effect of protein mutations on drug binding suggests ensuing personalised drug selection (2021) (5)
- [Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany]. (2003) (5)
- Vincristine, doxorubicin, cyclophosphamide, prednisone and etoposide (VACPE) in high-grade non-Hodgkin's lymphoma--a multicenter phase II study. (1995) (4)
- Images in cardiovascular medicine. Infarction-like electrocardiographic changes due to a myocardial metastasis from a primary lung cancer. (2007) (4)
- Infarction-Like Electrocardiographic Changes Due to a Myocardial Metastasis From a Primary Lung Cancer (2007) (4)
- MAGE-C1/CT7 spontaneously triggers a CD4+ T-cell response in multiple myeloma patients (2013) (4)
- Spontaneous and antibody-dependent cellular immune reactions to ethanol-altered hepatoma cells. (2008) (3)
- Targeted Exome Sequencing Identifies Novel Mutations in Familial Myeloproliferative Neoplasms Patients in the State of Qatar (2014) (3)
- Expression and immunogenicity of the cancer-testis antigen CT7 (MAGE-C1) in patients with multiple myeloma (2007) (3)
- Response to monoclonal antibodies in melanoma: specific or non-specific? (1986) (3)
- Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer (2015) (3)
- Cellular and humoral immune responses of cancer patients to defined tumor antigens. (2001) (3)
- Melanoma antibodies: specificity and interaction with melanoma and cytotoxic T-cells. (1984) (3)
- LUD01-014: Phase 1/2 study of chimeric monoclonal antibody cG250 in combination with vinblastine in patients with advanced renal cell carcinoma (ARCC). (2004) (2)
- Expression of a novel T-cell activation antigen on bile canaliculi. (1986) (2)
- LUD00-014: Phase I Study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) in patients with NY-ESO-1 or LAGE positive cancers (2004) (2)
- Randomized multicenter trial of sequential methotrexate (MTX) and 5-Fluorouracil (FU) vs FU alone in metastatic colorectal carcinoma (CRC) (1986) (2)
- First-in-human trial focusing on the immunologic effects of the survivin-derived multiepitope vaccine EMD640744. (2011) (2)
- Medullary thyroid cancer established in tissue culture (1987) (2)
- Chromosomal aberrations of cancer–testis antigens in myeloma patients (2015) (2)
- Cancer testis antigen expression and immune responses by prostate cancer patients: Implications for prognosis and immunotherapy. (2016) (2)
- Differentiation of Non-Adherent Hematopoietic Stem Cells from Umbilical Cord Blood Cells into Adherent Hepatocytic Lineage. (2006) (2)
- Cancer immunity hits multiple myeloma (2005) (2)
- Irinotecan in Second-Line Therapy of Metastatic Colorectal Cancer (2000) (2)
- Correction: Phase I clinical study of the recombinant antibody-toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas (2006) (2)
- Abstract B1: Radiotherapy promotes tumor-specific effector CD8+ T cells via DC activation. (2013) (1)
- [Malignant melanoma of the mucous membranes of the upper aerodigestive tract. Clinical, histological and immunohistochemical characteristics]. (1991) (1)
- Vaccines in breast cancer (2001) (1)
- Challenges in adapting international best practices in cancer prevention, care, and research for Qatar. (2014) (1)
- Synergistic therapeutic activity of chimeric G250-TNF and IFNγ for the treatment of renal cell cancer (2008) (1)
- Antibody and T-cell responses to the NY-ESO-1 antigen (2003) (1)
- [Penetrating duodenal ulcer as a complication of a hepatic artery port catheter in hepatic metastasis of sigmoid carcinoma]. (1997) (1)
- Autologous Stem Cell Transplantation : Leukapheresis Product has Anti-angiogenic Effects In Vivo Correlating with Neutrophil-derived VEGFR 1 (2012) (1)
- [Adjuvant therapy in cancer of the large intestine]. (1988) (1)
- Precision Medicine and Non-Colorectal Cancer Liver Metastases: Fiction or Reality? (2015) (1)
- Efficacy of selective digestive decontamination in patients with multiple myeloma undergoing high-dose chemotherapy and autologous stem cell transplantation (2018) (1)
- Imagine a world without cancer (2014) (1)
- [New antibodies in cancer treatment]. (2004) (1)
- 174 Intensive chemotherapy (idarubicin, ARA-C, VP-16) combined with G-CSF-priming yields high remission rates in patients with advanced MDS and high-risk AML (1997) (1)
- 6655 The emerging role of the novel serum marker GOLPH2 in detecting and monitoring of hepatocellular carcinoma (2009) (1)
- Miniatures Spontaneous Peripheral T-cell Responses toward the Tumor-Associated Antigen Cyclin D 1 in Patients with Clear Cell Renal Cell Carcinoma (2013) (1)
- PEG-liposomal doxorubicin (PLD) at 40mg/m2 versus 50mg/m2 every month for patients with metastatic breast cancer: A comparative analysis of two prospective phase II studies (2005) (1)
- Fludarabine Plus Epirubicin in Untreated or Minimal Pretreated Patients with Chronic Lymphocytic Leukemia – Preliminary Results of a Phase-ll Study (1997) (1)
- Identifying Novel Mutations In Familial Myeloproliferative Neoplasms Patients In The State Of Qatar Via Targeted Exome Sequencing Approach. (2014) (0)
- RAB 38 / NY-MEL-1 in Melanoma Patients the Melanocyte Differentiation Antigen Spontaneous CD 8 T Cell Responses against Alfred (2006) (0)
- ‘Cancer — testis’ antigen-expression in prostate carcinoma (1997) (0)
- Sa1677 Integrin αvβ6 (ITGB6) Is a Novel Serum Tumor Marker in Colorectal Cancer (CRC) Patients and Is Associated With Invasion and Metastasis of CRC (2013) (0)
- [Liver CT with portal vein administration of a contrast medium]. (1987) (0)
- Isolated, nucleic acid molecules for cancer-associated antigens encoding antigenic per se and their applications (2000) (0)
- Peptide vaccination for melanoma: 048 (1997) (0)
- [Therapy of inoperable cancers of the exocrine pancreas and liver]. (1991) (0)
- Tissues Human Malignant Melanoma , Epithelial Tumors , and Normal inD 3 Immunohistochemical Localization of Ganglioside G Updated (2006) (0)
- [Perspectives for tumour immunology: antigen-specific immunotherapy of malignant diseases]. (2001) (0)
- Phase I trial of huA33 antibody plus 5-fluorouracil (5FU), leucovorin, and oxaliplatin in patients with metastatic colorectal cancer [LUD2003–005] (2007) (0)
- Abstract 5530: Evidence for immunological pressure and escape from longitudinal analysis of the expression of and immune responses against NY-ESO-1 in a patient with metastatic melanoma (2011) (0)
- [Tumor-associated and epithelial markers in gastrointestinal tumors]. (1991) (0)
- The breast differentiation antigen NY-BR-1: A novel target antigen for active immunotherapy in breast cancer. (2004) (0)
- Anticorps se liant à mage a3 (2012) (0)
- Targets for immunotherapy in breast cancer (2001) (0)
- Chemotherapy with Idarubicin, Ara-C,VP-16, Amsacrine, Followed by G-CSF and Maintenance Immunotherapy with Interleukin-2 for Patients with High-Risk Acute Myeloid leukemia: a 3-Years Follow-Up (1998) (0)
- Expansion of Umbilical Cord Blood Hematopoietic Stem Cells for Clinical Use. (2007) (0)
- Abstract A18: Mouse models of autochthonous cancer to study local immune subversion. (2013) (0)
- PD-L1 blockade during ex vivo expansion of virus-specific T cells for the treatment of infections after allogeneic hematopoietic stem cell transplantation modulates the phenotype and functional activity of T cells (2018) (0)
- Title Page / Editorial Board / Contents / Imprint / Guidelines for Authors (2015) (0)
- Long-termComplete Remission Following Radiosurgery and Immunotherapy in aMelanomaPatientwithBrainMetastasis : Immunologic Correlates (2014) (0)
- Stomach signet-ring cancer cell line (MZ-STO-1), established in tissue culture: Morphological characterization and antigenic profile (1986) (0)
- Tumor antigen-encoding mRNA for the analysis of spontaneousand vaccine-induced immune responses in cancer patients (2008) (0)
- CHALLENGES IN THE SPECIFIC IMMUNOTHERAPY OF CANCER (1999) (0)
- Vol. 23, Supplement 4, April 2000 (2000) (0)
- Induction of specific T-cell responses in vitro and in vivo with melanoma associated peptides (2007) (0)
- Combination therapy comprising the tumor associated antigen-binding antibodies (2012) (0)
- [Molecular targeted therapy]. (2006) (0)
- Tumor-Reactive CTL Analogues Capable of Improved Stimulation Identification of NY-ESO-1 Peptide and Vincenzo (2000) (0)
- Contents Vol. 31, 2015 (2015) (0)
- [Cancer immunotherapy--current status]. (2006) (0)
- Cancer vaccine development in solid tumors (2003) (0)
- Subject Index Vol. 52,1995 (1995) (0)
- Undifferentiated sarcoma arising in the brain, 23 years after curative treatment of an ependymoma (2005) (0)
- Neoadjuvant gemcitabine/cisplatin for resectable adenocarcinoma of the pancreatic head—a prospective phase I trial (2007) (0)
- Monoclonal antibodies define epithelial markers epm 1 exo 1 on gastrointestinal tumors in human secretions and serum samples (1987) (0)
- Palliative treatment for advanced gastrointestinal cancer: is response a suitable end-point? (1996) (0)
- Epithelial (EPM-1) and exocrine (EXO-1) cell markers define gastrointestimal tumors (1986) (0)
- LUD01–014: Phase 1/2 study of chimeric monoclonal antibody cG250 in combination with vinblastine in patients with advanced renal cell carcinoma (ARCC) (2004) (0)
- Adjuvante und palliative Therapie kolorektaler Karzinome (2008) (0)
- Hodgkin lymphoma after first line therapy: Do we need FDG-PET/CT surveillance? (2009) (0)
- Subject Index Vol. 64, 2003 (2003) (0)
- T-lymphocytotoxicity in malignant melanoma: Induction with autologous mutagenized tumor cell clones (1986) (0)
- GD3 ganglioside: A marker for the diagnosis and treatment of neuroectodermal tumors? (1986) (0)
- [Identification of tumor antigens: strategies and perspectives]. (2004) (0)
- Contents Vol. 82, 2012 (2012) (0)
- Immune Response in Patients with Cancer Cryptic Epitopes Induce High-Titer Humoral (2010) (0)
- Enhancing NY-ESO-1 antigen expression in lung cancer cells through gene hypomethylation using 5-Aza-2′-deoxycytidine (2018) (0)
- [Chemotherapy of colorectal cancer]. (1989) (0)
- Activation T Cells via Dendritic Cell + Effector CD8 Radiotherapy Promotes Tumor-Specific (2012) (0)
- Immune responses to peptide-based cancer vaccines (1997) (0)
- A cancer associated with antigen-encoding isolated nucleic acid molecule, which uses antigen itself, and its (1997) (0)
- [New drugs for colorectal cancer]. (2004) (0)
- Year : 2011 Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting : a Swiss single centre experience (2011) (0)
- [Identification of tumor antigens: strategies and perspectives]. (2006) (0)
- Cancer vaccines and immunotherapy: CTL-defined cancer vaccines in melanoma and other epithelial cancers (2000) (0)
- Abstract 4741: Therapeutic efficacy of a human-derived antibody against cancer-testis antigen NY-ESO-1 (2011) (0)
- Expansion of umbilical cord blood mesenchymal stem cells. (2016) (0)
- patients undergoing peptide immunotherapy (2001) (0)
- Therapy of Advanced MDS, AML Evolving from MDS, or Secondary AML with Idarubicin Ara-C, VP-16, Followed by G-CSF-Priming Exhibits High Remission Rate (1998) (0)
- [The Tumor Immunology Study Group: tumor immunology of the gastrointestinal tract--experimental and clinical experiences]. (1988) (0)
- Tissue-specific ING 1 Transcripts and a Homologue Gene Product Are Breast Cancer Antigens : Characterization of Tumor Suppressor Gene ING 1 Cancer-Testis Antigens and Updated (1999) (0)
- Targets for Passive Immunotherapy Intracellular Tumor-Associated Antigens Represent Effective (2012) (0)
- GCA-2: A new marker for gastrointestinal tract cancer (1986) (0)
- Combination therapy includes antibodies binding tumor associated antigens (2012) (0)
- 1 Long-term Complete Remission following Radiosurgery and Immunotherapy in a Melanoma Patient with Brain Metastasis: Immunological Correlates (2008) (0)
- Computerized image analyses of sperm motion: influence of swin-up and cryopreservation on 20 tours profiles in ejaculates of fertile men (1987) (0)
- Cryopreservation and swin-up procedure on the sperm motility characteristics of fertile men: 20 hours evolution of movement parameters as measured by a computerized semen analyser (1989) (0)
- Contents Vol. 64, 2003 (2003) (0)
- Preparations of immunogenic molecules that granulocyte macrophage-stimulating factor included as adjuvant (1997) (0)
- Hepatocellular carcinoma: Biochemical and antigenic markers of three established cell lines (1986) (0)
- Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study (2018) (0)
- 222 Induction of specific T-cell responses in vitro and in vivo with melanoma associated peptides (1995) (0)
- [Adjuvant and palliative chemotherapy for stomach carcinoma]. (1995) (0)
- Cancer vaccination strategies targeting NY-ESO-1 (2003) (0)
- Nonprofessional APCs from Exogenous NY-ESO-1 Polypeptides by Cross-Presentation of HLA Class I Epitopes (2003) (0)
- [Adjuvant and palliative therapy for colorectal carcinoma]. (1994) (0)
- Abstract 5516: Therapeutic vaccination with the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors (2011) (0)
- [Myelomonocytic leukemia: clinical, cytological, and cytogenetic studies of acute, subacute, and chronic forms (author's transl)]. (1977) (0)
- New immunotherapeutical approaches in melanoma: 46 (1995) (0)
- [New aspects of tumor immunology. Importance of the T-cell system]. (1982) (0)
- 6.4 Cancer immunity and clinical oncology (2010) (0)
- Chromosome abnormality in a human TCGF-dependent T-lymphocyte culture generated against autologous melanoma cells in vitro. (1983) (0)
- Late abstracts 186–187 (2005) (0)
- Hematopoietic stem cell transplantation in qatar: One-year anniversary. (2017) (0)
- RAB38/NY-MEL-1 in Melanoma Patients the Melanocyte Differentiation Antigen Spontaneous CD8 T Cell Responses against (2013) (0)
- HLA-restricted recognition of human melanoma antigens by cytolytic T-lymphocytes—two CTL-defined antigens shared by human melanoma cells and recognized in association with HLA-A2: 73 (1993) (0)
- Peptide Vaccines in Melanoma Patients (1997) (0)
- Mendez Analysis of HLA class I expression in A . Serrano different metastases from two melanoma (0)
- HLA-DP 4 expression and immunity to NY-ESO-1 : correlation and characterization of cytotoxic CD 4 + CD 25-CD 8-T cell clones (2004) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Alexander K. Knuth?
Alexander K. Knuth is affiliated with the following schools:
